In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone
about
sameAs
Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophiliaComparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacinGatifloxacin: a new fluoroquinolone.Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitisComparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci.Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters.Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections.Efficacy of gatifloxacin in experimental Escherichia coli meningitis.In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteriaPrevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory seMechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.Staphylococcus aureus mutants selected by BMS-284756.Cultivation of Neisseria gonorrhoeae in liquid media and determination of its in vitro susceptibilities to quinolones.Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae.In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.The new fluoroquinolones: A critical reviewEffect of linezolid on the 50% lethal dose and 50% protective dose in treatment of infections by Gram-negative pathogens in naive and immunosuppressed mice and on the efficacy of ciprofloxacin in an acute murine model of septicemia.Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones.Primary targets of fluoroquinolones in Streptococcus pneumoniae.Postantibiotic effects of gatifloxacin against gram-positive and -negative organisms.Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers.In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases.Gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis: safety, efficacy and patient perspective.Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinoloneUptake and intracellular activity of AM-1155 in phagocytic cells.The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3.In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.Effects of gatifloxaine content in gatifloxacine-loaded PLGA and β-tricalcium phosphate composites on efficacy in treating osteomyelitis.Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers.Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus.CE-ECL detection of gatifloxacin in biological fluid after clean-up using SPE.Usefulness of simultaneous and sequential monitoring of glucose level and electrocardiogram in monkeys treated with gatifloxacin under conscious and nonrestricted conditions.History of antibiotics: from fluoroquinolones to daptomycin (Part 2).
P2860
Q24533461-5E86556D-263F-437B-9E2A-63A68A53BC46Q28378625-E4DFEE3F-D07F-4A57-BA89-57D2D711BC0FQ31522155-F561D4C5-8C41-414C-8214-9925750AC3A2Q33697562-5A27565C-BCBF-40D3-BC2E-8AD1717A3B2CQ33699541-5FF3028B-26C0-401B-AB17-78FB82AA6835Q33751682-BE4825CB-A392-4120-BF32-6D89E4C7BE16Q33895157-BB1B5DA0-3D48-4731-B2EB-12DFFBD06B93Q33976981-44F79666-2F71-4ED4-87A5-A27BE1B89A16Q33977276-24D0D119-57F0-429B-911C-9EE0CE46F075Q33978131-C70D95F7-7626-467F-A5B3-D9B0293764F6Q33978849-9EF8461C-7E19-4DEA-A253-EAA290A9E23FQ33983092-FBA2ADC9-2170-458B-98DA-0D062FD54F98Q33983475-ADC28DBD-1E47-4521-8207-B5E915618017Q34042257-9F596B71-04E9-4346-AA16-8CD7AF002A08Q34721556-897AEEE6-AD76-44F0-A6F8-719F3B10A7F6Q35136707-117FF336-EEEB-422C-A36A-7AA415A3E145Q35649595-06AC3FD3-A4FB-465C-B4DC-3A260A70B577Q36172366-72437359-D3E5-43FC-B4A9-119FFFF54C7DQ36825816-CF5C364C-A8AE-4244-868B-36767E563931Q39469902-2E11F8E4-4BD1-44E8-92F6-10DF8DB39719Q39472095-C5270B4E-CC2B-480A-8E6D-791F9ECB857CQ39476038-6F3CD34E-5FF0-47A1-8D9F-F243D36AEB27Q39476076-1DD91188-27CB-4AA3-A5BE-B857CD05BA5DQ39477371-3E22828B-257C-4D61-90E4-B1B79F8280ECQ39558211-FECE8BEB-119B-4BE2-8587-D650938EF535Q39559188-A252A7D3-0D76-4ECC-B15C-C9F28B4BF814Q39675169-F2F14581-331E-48C2-AA27-14A6B6B15543Q39780917-3644CAB9-A05B-4EE8-96E4-438A9C18F05DQ39782054-1490EF40-5393-429A-B8B5-D0A3A90247D1Q39783263-10B160BA-FD72-4FF6-BB41-1FEEFF4638CAQ40220025-D3A92026-3CA8-4B48-93E2-BEC076A97B07Q40285332-42AF3963-6BA5-4B82-84B4-F4C41DB80396Q41586328-E4F57301-B1BB-4E58-BB86-5809C7447F38Q42408718-71DD3FED-DF10-4882-8FE4-A84E424064D2Q42622286-DC332D4B-86D4-4D4B-8CD5-7DFC4678315EQ42784827-285367E3-27E3-4595-A6B5-0981372D8C62Q43258418-677B9561-CF5E-4949-A31F-285B932C9592Q47195199-039DE6A3-68CC-471A-8B6C-46671247F8DCQ48202873-CBE74E4D-7D37-4BBE-B39C-FB88A458D92F
P2860
In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone
description
1992 nî lūn-bûn
@nan
1992 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
In vitro and in vivo antibacte ...... w 6-fluoro-8-methoxy quinolone
@ast
In vitro and in vivo antibacte ...... w 6-fluoro-8-methoxy quinolone
@en
In vitro and in vivo antibacte ...... w 6-fluoro-8-methoxy quinolone
@nl
type
label
In vitro and in vivo antibacte ...... w 6-fluoro-8-methoxy quinolone
@ast
In vitro and in vivo antibacte ...... w 6-fluoro-8-methoxy quinolone
@en
In vitro and in vivo antibacte ...... w 6-fluoro-8-methoxy quinolone
@nl
prefLabel
In vitro and in vivo antibacte ...... w 6-fluoro-8-methoxy quinolone
@ast
In vitro and in vivo antibacte ...... w 6-fluoro-8-methoxy quinolone
@en
In vitro and in vivo antibacte ...... w 6-fluoro-8-methoxy quinolone
@nl
P2093
P2860
P356
P1476
In vitro and in vivo antibacte ...... w 6-fluoro-8-methoxy quinolone
@en
P2093
P2860
P304
P356
10.1128/AAC.36.10.2108
P407
P577
1992-10-01T00:00:00Z